4.4 Article

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary

期刊

JOURNAL OF CLINICAL LIPIDOLOGY
卷 8, 期 5, 页码 473-488

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2014.07.007

关键词

Clinical recommendations; Dyslipidemia; Atherogenic cholesterol; Low-density lipoprotein cholesterol; Lipoproteins; Atherosclerotic cardiovascular disease; Coronary heart disease

资金

  1. Merck and Co.
  2. Amarin
  3. AstraZeneca
  4. Regeneron/Sanofi-Aventis
  5. Kowa Pharmaceuticals
  6. Abbott Laboratories
  7. Matinas BioPharma
  8. Astra Zeneca
  9. Pharmavite
  10. Trygg Pharmaceuticals
  11. Merck
  12. Arena Pharmaceuticals
  13. Boehringer Ingelheim
  14. Cargill Inc.
  15. GlaxoSmithKline
  16. Novo Nordisk
  17. Orexigen Therapeutics
  18. Shionogi
  19. Takeda
  20. Stratum Nutrition
  21. California Raisin Board
  22. Esperion
  23. Essentialis
  24. Forest
  25. Gilead
  26. Given
  27. Hoffman LaRoche
  28. Home Access
  29. Novartis
  30. Omthera
  31. Pfizer
  32. TWI Bio
  33. Xoma
  34. Ardea Inc.
  35. High Point Pharmaceuticals
  36. LLC
  37. Micropharma Limited
  38. Transtech Pharma, Inc.
  39. TIMI
  40. Pozen
  41. Regeneron
  42. Elcelyx
  43. Amgen
  44. Bristol-Myers Squibb
  45. Catabasis
  46. Daiichi Sankyo, Inc.
  47. Eisai
  48. VIVUS
  49. Zeomedex
  50. WPU
  51. Sanofi
  52. Lily
  53. Philips Medical Systems
  54. Merck Sharpe Dohme
  55. Novo Nordisk Inc.
  56. Genzyme
  57. Pfizer, Inc.
  58. LipoScience, Inc.
  59. Medtelligence
  60. Vindico

向作者/读者索取更多资源

Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia. (C) 2014 National Lipid Association. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据